News

The Latest Information about i-FACTOR and Cerapedics

Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data

i-FACTOR® Peptide Enhanced Bone Graft continues to demonstrate statistical superiority to autologous bone in cervical spine surgery

Find out more

Cerapedics Announces Expansion of Colorado Headquarters

Ortho-biologics company adds 10,000 square feet and doubles employee headcount at Denver metropolitan headquarters

Find out more

New V.P. of Clinical and Market Development

Cerapedics Appoints Patrick O’Connor as Vice President of Clinical and Market Development

Find out more

Cerapedics announces ISASS bone grafting policy statement

Society states company's drug-device combination technology shown to be safe and effective as autograft replacement with compelling clinical evidence .

Find out more

Cerapedics named company of the year

MedTech Outlook’s Top 10 Orthopedic Solution Providers.

Find out more

Cerapedics named as a finalist for company of the year

The finalists are in for the 10th annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, will honor the pharmaceutical and medical device industries’ most influential innovators.

Find out more

Cerapedics announces first patients enrolled in IDE Clinical Trial of P-15L Bone Graft for transforaminal lumbar interbody fusion surgery

Proprietary synthetic small peptide technology (P-15) is being evaluated in patients across the U.S. with degenerative disk disease

Find out more

Cerapedics announces closing of $22 million financing

Funding will accelerate commercialization and U.S. lumbar trial for i-FACTOR™ Peptide Enhanced Bone Graft

Find out more

Cerapedics receives 2018 MedTech Breakthrough Award

Best New Surgical Technology Solution

Find out more

Cerapedics announces results from IVANOS study of i-FACTOR Peptide Enhanced Bone Graft

Single-center randomized trial is measuring the efficacy of i-FACTOR in lumbar posterolateral spine surgery

Find out more